Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Human tissue kallikrein

Recombinant protein · developed by DiaMedica Therapeutics

Phase 2/3 Most advanced trial

DMAC Developer

1 Registered trials

What is Human tissue kallikrein?

DM199 is recombinant human tissue kallikrein administered intravenously followed by subcutaneous doses. It is being studied in acute ischemic stroke.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Recombinant protein
Therapy area: Neurology
Developer: DiaMedica Therapeutics Inc (DMAC)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2/3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05065216	Phase 2/3	Acute Stroke	Recruiting	DMAC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute StrokeIschemic StrokeStroke

More from DiaMedica Therapeutics

DM199 Phase 2

Sources

ClinicalTrials.gov NCT05065216

Updated Oct 3, 2026. Something wrong or missing? Report it on the DMAC page.

Follow DMAC, the company behind Human tissue kallikrein

See DMAC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

DMAC catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z